PRESS INFORMATION BUREAU
पत्र सूचना कार्यालय
GOVERNMENT OF INDIA
भारत सरकार

Business Line, Delhi
Saturday 14th December 2013, Page: 2
Width: 7.96 cms, Height: 5.93 cms, a4, Ref: pmin.2013-12-14.38.16

Aurobindo Pharma gets USFDA nod for anti-depressant

Hyderabad, Dec. 13

Aurobindo Pharma Ltd has received the final approval from the US Food & Drug Administration to manufacture and market duloxetine hydrochloride delayed-release capsules. The capsules are the generic equivalent of Eli Lilly's Cymbalta delayed-release capsules and are indicated for the treatment of major depressive disorders under the neurological therapeutic category. The market size of the product is estimated to be $5.4 billion for the 12 months ending September 2013. Hyderabad-based Aurobindo Pharma now has a total of 188 ANDA approvals from USFDA, according to a release issued on Friday. — **Our Bureau**

Company / Regulatory